A $2 Billion Valuation Built on America's Favorite Drug

Miami telehealth firm eMed hits $2B+ valuation with a bold AI-powered GLP-1 employer play

1 Jun 2026

Only one in five American employers covers GLP-1 drugs. That gap, between what workers want and what companies pay for, has just attracted $200m.

eMed, a Miami-based telehealth firm, closed a Series A round on March 26th, 2026, crossing a $2bn valuation in the process. Aon Consulting led the deal. Linda Yaccarino, formerly chief executive of X, now runs eMed. Tom Brady, the footballer, holds the title of founding chief wellness officer. Whether either appointment accelerates clinical outcomes remains to be seen.

The company's pitch is structural rather than transactional. Rather than selling prescription access, eMed partners with employers to deliver managed GLP-1 programs that combine drug fulfilment, continuous care support, and an AI layer designed to keep patients engaged at the moments when dropout risk peaks. GLP-1 adherence among its members, the firm reports, stands at 90%, more than twice the industry norm. Average weight loss per member is 21 pounds. An independent study by University College London, covering more than 8,000 patients, is under peer review at Nature Medicine.

Fresh capital will scale the AI platform and fund a capitated care model, one where employers pay a fixed amount per member rather than absorbing open-ended pharmacy bills. That structure is a meaningful departure from how most point solutions are priced and, if it holds, a more defensible business.

Broader conditions favour the bet. According to Rock Health, American digital health startups raised $4bn across 110 deals in the first quarter of 2026, the strongest opening since pandemic-era highs, with capital concentrating in AI-native platforms built for complex clinical workflows.

GLP-1s are projected to reach $150bn in annual global sales within a decade. Employers absorbing spiralling pharmacy budgets have no obvious alternative. Whether eMed's integrated model outperforms the point solutions that preceded it is the question its UCL study will eventually have to answer.